{
    "clinical_study": {
        "@rank": "62141", 
        "arm_group": {
            "arm_group_label": "TRAVATAN Z\u00ae", 
            "arm_group_type": "Experimental", 
            "description": "Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in both eyes once daily at 9PM for 3 months."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate IOP reduction efficacy of travoprost 0.004%\n      ophthalmic solution (TRAVATAN Z\u00ae) in subjects with normal tension glaucoma using TRAVATAN Z\u00ae\n      monotherapy."
        }, 
        "brief_title": "Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Normal Tension Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension", 
                "Low Tension Glaucoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of normal tension glaucoma.\n\n          -  Must sign an Informed Consent form.\n\n          -  IOP within protocol-specified range.\n\n          -  Other protocol-specified inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Pregnant and lactating women, or women who intend to become pregnant during the study\n             period.\n\n          -  Advanced and serious glaucoma, as specified in protocol.\n\n          -  Complicated chronic or recurrent uveitis, scleritis or corneal herpes.\n\n          -  History of ocular trauma, intraocular surgery or laser surgery for the included eye.\n\n          -  Ocular-infection and severe ocular complication.\n\n          -  Best-corrected visual acuity (BCVA) worse than 0.2 decimal.\n\n          -  Difficulty in conducting applanation tonometry for the included eye as determined by\n             the doctor.\n\n          -  Severe or serious hypersensitivity to prostaglandin analogues or any ingredients used\n             in the study.\n\n          -  Use of IOP lowering ophthalmic solutions other than TRAVATAN Z\u00ae or oral carbonic\n             anhydrase inhibitor (Diamox, etc.) during the study period.\n\n          -  Use of any adrenocorticosteroids during the study period.\n\n          -  Use of IOP lowering ophthalmic solution within the past 30 days.\n\n          -  Regarded by doctor as not suitable for study participation.\n\n          -  Other protocol-specified exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995136", 
            "org_study_id": "M-13-047"
        }, 
        "intervention": {
            "arm_group_label": "TRAVATAN Z\u00ae", 
            "description": "benzalkonium chloride (BAC) free", 
            "intervention_name": "Travoprost Ophthalmic Solution 0.004%", 
            "intervention_type": "Drug", 
            "other_name": "TRAVATAN Z\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Travoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Glaucoma", 
            "Ocular hypertension"
        ], 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Investigation of IOP Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma", 
        "overall_contact": {
            "email": "alcon.medinfo@alcon.com", 
            "last_name": "Alcon Call Center", 
            "phone": "1-888-451-3937"
        }, 
        "overall_official": {
            "affiliation": "Alcon Japan, Ltd.", 
            "last_name": "Danyel Carr, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "IOP (fluid pressure inside the eye) will be assessed using Goldmann applanation tonometry and is measured in millimeters of mercury (mmHg). Data from 4, 8, and 12 weeks will be pooled, and a negative change indicates an improvement.", 
            "measure": "Mean change from baseline in IOP at 9AM", 
            "safety_issue": "No", 
            "time_frame": "Baseline (Day 0), Up to Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995136"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}